Your browser doesn't support javascript.
loading
Unbiased proteomics identifies plasminogen activator inhibitor-1 as a negative regulator of endothelial nitric oxide synthase.
Garcia, Victor; Park, Eon Joo; Siragusa, Mauro; Frohlich, Florian; Mahfuzul Haque, Mohammad; Pascale, Jonathan V; Heberlein, Katherine R; Isakson, Brant E; Stuehr, Dennis J; Sessa, William C.
Affiliation
  • Garcia V; Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.
  • Park EJ; Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.
  • Siragusa M; Institute for Vascular Signaling, Centre for Molecular Medicine, Goethe University, 60596 Frankfurt am Main, Germany.
  • Frohlich F; Vascular Biology and Therapeutics Program, Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.
  • Mahfuzul Haque M; Department of Biology/Chemistry, Molecular Membrane Biology Section, University of Osnabrück, 49076 Osnabrück, Germany.
  • Pascale JV; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.
  • Heberlein KR; Department of Pharmacology, New York Medical College, Valhalla, NY 10595.
  • Isakson BE; Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, VA 22908.
  • Stuehr DJ; Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, VA 22908.
  • Sessa WC; Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195.
Proc Natl Acad Sci U S A ; 117(17): 9497-9507, 2020 04 28.
Article in En | MEDLINE | ID: mdl-32300005
ABSTRACT
Nitric oxide (NO) produced by endothelial nitric oxide synthase (eNOS) is a critical mediator of vascular function. eNOS is tightly regulated at various levels, including transcription, co- and posttranslational modifications, and by various protein-protein interactions. Using stable isotope labeling with amino acids in cell culture (SILAC) and mass spectrometry (MS), we identified several eNOS interactors, including the protein plasminogen activator inhibitor-1 (PAI-1). In cultured human umbilical vein endothelial cells (HUVECs), PAI-1 and eNOS colocalize and proximity ligation assays demonstrate a protein-protein interaction between PAI-1 and eNOS. Knockdown of PAI-1 or eNOS eliminates the proximity ligation assay (PLA) signal in endothelial cells. Overexpression of eNOS and HA-tagged PAI-1 in COS7 cells confirmed the colocalization observations in HUVECs. Furthermore, the source of intracellular PAI-1 interacting with eNOS was shown to be endocytosis derived. The interaction between PAI-1 and eNOS is a direct interaction as supported in experiments with purified proteins. Moreover, PAI-1 directly inhibits eNOS activity, reducing NO synthesis, and the knockdown or antagonism of PAI-1 increases NO bioavailability. Taken together, these findings place PAI-1 as a negative regulator of eNOS and disruptions in eNOS-PAI-1 binding promote increases in NO production and enhance vasodilation in vivo.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Gene Expression Regulation, Enzymologic / Plasminogen Activator Inhibitor 1 / Nitric Oxide Synthase Type III Type of study: Prognostic_studies Limits: Humans Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Gene Expression Regulation, Enzymologic / Plasminogen Activator Inhibitor 1 / Nitric Oxide Synthase Type III Type of study: Prognostic_studies Limits: Humans Language: En Year: 2020 Type: Article